Vanguard Health Care ETF (VHT) Covered Calls
The Vanguard Health Care ETF seeks to track the investment results of the MSCI US Investable Market Health Care 25/50 Index. It provides comprehensive exposure to the U.S. healthcare sector, spanning pharmaceuticals, biotechnology, healthcare equipment, and managed care. With over 400 holdings and an industry-leading low expense ratio, VHT is a core building block for investors seeking broad-based participation in healthcare innovation, aging demographics, and medical advancements.
You can sell covered calls on Vanguard Health Care ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for VHT (prices last updated Tue 4:16 PM ET):
| Vanguard Health Care ETF (VHT) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 272.33 | +5.97 | 272.35 | 272.55 | 120K | - | 5.8 |
| Covered Calls For Vanguard Health Care ETF (VHT) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 270 | 4.40 | 268.15 | 0.7% | 14.2% | |
| May 15 | 270 | 8.00 | 264.55 | 2.1% | 16.7% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
The Vanguard Health Care ETF (VHT) is a premier sector fund designed to capture the full breadth of the U.S. healthcare ecosystem. By tracking the MSCI US Investable Market Health Care 25/50 Index, the fund offers a diversified portfolio that balances high-growth biotechnology with stable, cash-generating pharmaceutical and insurance giants. In early 2026, VHT has benefited significantly from the continued expansion of the GLP-1 market and a resurgence in biotech M&A activity, as large-cap players seek to replenish their pipelines ahead of major patent expirations.
The fund’s portfolio is exceptionally deep, holding approximately 412 securities. As of March 2026, the fund is heavily anchored by Eli Lilly and Company (approx. 12.7%), which has seen its valuation soar due to leadership in metabolic health. Other core holdings include Johnson & Johnson (8.2%), AbbVie (6.0%), and UnitedHealth Group (4.0%). Sector allocation is strategically spread across Pharmaceuticals (32%), Biotechnology (22.5%), and Health Care Equipment (18.4%), providing a "one-stop-shop" for investors. Vanguard’s signature efficiency is evident here, with a rock-bottom expense ratio of 0.09%—significantly lower than the category average.
Competitive Landscape
VHT competes in a high-stakes arena of healthcare investment vehicles. Its primary rival is the Health Care Select Sector SPDR Fund (XLV). While XLV is the most liquid and focuses strictly on S&P 500 large-caps, VHT provides a broader reach by including mid- and small-cap companies, which can offer higher growth potential. For investors looking for more targeted exposure, the SPDR S&P Biotech ETF (XBI) is the standard for pure biotech volatility, and the iShares U.S. Healthcare ETF (IYH) offers a similar broad-market approach with different weighting constraints.
Because of its immense AUM (approx. $20 billion) and steady volume, VHT maintains a liquid options market. It is a staple for income-focused investors who utilize covered calls to monetize the consistent, non-cyclical demand for healthcare services, especially during periods of broader market volatility or "risk-off" sentiment.
Strategic Outlook and Innovation
The strategic narrative for VHT in 2026 is centered on "Healthcare AI 2.0." The industry has moved beyond pilot programs into enterprise-scale implementation, with AI-driven drug discovery labs—such as the landmark Lilly-Nvidia partnership—becoming the new standard for R&D. Furthermore, the 2025 "One Big Beautiful Bill Act" (OBBBA) has begun to reshape the economic landscape for pharmacies and PBMs, forcing a shift toward value-based care models that favor the large, integrated players held within VHT.
Looking forward, VHT is positioned as a primary beneficiary of the global "longevity" trend. As the median age of the U.S. population continues to climb, the demand for the chronic care management and medical devices represented in this fund is expected to remain robust. With a solid dividend yield of approximately 1.6% and a track record of outperforming the broader market during defensive cycles, VHT remains the standard-bearer for low-cost, diversified healthcare exposure in the mid-2020s.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | QQQ covered calls | 1. | REPL covered calls | |
| 2. | EEM covered calls | 7. | GLD covered calls | 2. | TLRY covered calls | |
| 3. | NVDA covered calls | 8. | TLT covered calls | 3. | NKE covered calls | |
| 4. | KWEB covered calls | 9. | HYG covered calls | 4. | RCAT covered calls | |
| 5. | SPY covered calls | 10. | EWZ covered calls | 5. | CMPX covered calls | |
Want more examples? VGZ Covered Calls | VIAV Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
